Grace Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Grace Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$71K	–	171
2021 Q2	$71K	Hold	400	–	–	0.05%	156
2021 Q1	$66K	Hold	400	–	–	0.04%	202
2020 Q4	$66K	Hold	400	–	–	0.04%	206
2020 Q3	$57K	Hold	400	–	–	0.04%	199
2020 Q2	$44K	Hold	400	–	–	0.04%	182
2020 Q1	$40K	Hold	400	–	–	0.04%	149
2019 Q4	$60K	Buy	+400	New	+$54.4K	0.05%	159
2019 Q3	–	Sell	-400	Closed	-$57K	–	159
2019 Q2	$57K	Sell	400 -500	-56%	-$67.2K	0.03%	175
2019 Q1	$129K	Sell	900 -200	-18%	-$26.1K	0.05%	177
2018 Q4	$136K	Buy	1,100 +600	+120%	+$89K	0.06%	179
2018 Q3	$84K	Hold	500	–	–	0.03%	182
2018 Q2	$86K	Buy	+500	New	+$81.7K	0.03%	190

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Grace Capital's JAZZ Position: Q3 2021 in Review

Grace Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 400 shares — an estimated $71K sold.

Grace Capital first reported a position in JAZZ in Q2 2018 and held it in 12 quarters. The position peaked at $136K in Q4 2018. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Grace Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Grace Capital sold 400 Jazz Pharmaceuticals shares in Q3 2021, an estimated $71K.
Grace Capital first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 12 quarters.
Grace Capital's Jazz Pharmaceuticals position peaked at $136K in Q4 2018.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Grace Capital's 13F filing for Q3 2021, filed 8 Nov 2021.